Tetsuya Yamada, Managing Director, OMRON Healthcare, India
Being built with an investment of Rs 128 crore, this state-of-the-art facility will mark the company’s debut in the healthcare manufacturing space in India and will further strengthen its presence in the home healthcare device industry in the country as well as its global network of production facilities with locations in Japan, China, Vietnam, Italy and Brazil. In conversation with BioSpectrum Asia, Tetsuya Yamada, Managing Director, OMRON Healthcare India talks about the company’s growth plans in Asia. Edited excerpts:
What are the key global highlights at OMRON Healthcare for FY 2023-24?
OMRON Healthcare, worldwide, strives to work towards empowering people to live life to the fullest by providing them with innovative health monitoring and wellness devices. This endeavour is captured in its vision ‘Going For Zero’ which aims for propagating preventive care to achieve a society where there are Zero cerebrovascular and cardiovascular events, Zero aggravation of respiratory diseases and Zero restrictions of daily activities due to chronic pain. For FY 2023-24, the company’s key initiatives will focus on enhancing the reach and availability of digital BP monitors for hypertension management, coming up with more innovative devices for cardiovascular disease management and also accelerate further expansion in the Remote Patient Monitoring (RPM) services domain.
Are you planning to launch new products this year? Are there any new partnerships or investments in the pipeline?
This story is from the BioSpectrum Asia Sep 2023 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the BioSpectrum Asia Sep 2023 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.
